What to Take for Chronic Constipation: OTC to Rx

Chronic constipation treatment follows a stepped approach, starting with inexpensive over-the-counter options and escalating to prescription drugs only when those fail. The 2023 joint guideline from the American Gastroenterological Association and American College of Gastroenterology lays out a clear sequence: fiber supplements first, then osmotic laxatives like polyethylene glycol (PEG), then stimulant laxatives for short-term or rescue use, and finally prescription secretagogues or prokinetics for people who don’t respond to any of those.¹ Where you start on that ladder depends on how severe your symptoms are, what’s causing them, and what you’ve already tried.

Fiber Supplements as a Starting Point

Clinical guidelines suggest fiber supplementation as a first-line treatment for chronic idiopathic constipation, though the evidence behind that recommendation is rated as low certainty. That doesn’t mean fiber doesn’t work; it means the studies that exist are small or imperfect. A 2022 meta-analysis of randomized controlled trials found that about two-thirds of participants responded to fiber treatment compared with roughly 40% on placebo, a meaningful difference.² Stool frequency went up and consistency improved, particularly at higher doses taken for four weeks or longer.

Not all fiber supplements are equal. Psyllium (the active ingredient in products like Metamucil) and pectin showed the strongest effects in that meta-analysis. Psyllium forms a viscous gel that holds water in the stool, softening it and adding bulk. Coarse wheat bran works through a different mechanism: its insoluble particles mechanically stimulate the intestinal lining, speeding transit.³ The particle size matters more than people realize. Coarse wheat bran softens stool by increasing its water content, but finely ground wheat bran actually decreases stool water content, potentially making constipation worse.⁴ If you’ve tried a wheat bran supplement without results, the grind may have been too fine.

The practical limitation of fiber is that many people find it causes bloating and gas, especially in the first week or two. Starting at a low dose and increasing gradually over a couple of weeks helps. But for people with slow-transit constipation where the colon barely moves at all, adding bulk to a system that can’t propel it forward sometimes makes symptoms worse rather than better.

Osmotic Laxatives

When fiber alone isn’t enough, osmotic laxatives are the next step and carry the strongest guideline endorsement of any OTC option. These work by drawing water into the intestinal lumen, softening stool and stimulating movement. PEG (sold as MiraLAX and generics) is the best-studied of the group. The AGA-ACG guideline gives PEG a strong recommendation with moderate certainty of evidence, the highest confidence level assigned to any OTC constipation treatment.¹

In a six-month trial, about three-quarters of patients taking PEG daily were symptom-free by the end of the study compared with a fifth on placebo. They also reported less straining, fewer hard stools, and lower use of additional laxatives.⁵ PEG isn’t absorbed into the bloodstream. It passes through the entire digestive tract bound to water molecules, which is part of why it has such a clean safety profile for long-term use.

Magnesium-based laxatives are another osmotic option. Magnesium hydroxide (milk of magnesia) is the most familiar, but magnesium oxide and magnesium citrate are also used. These retain water in the intestine by creating an osmotic gradient. Magnesium citrate is the strongest formulation and works more like a traditional osmotic laxative, while magnesium hydroxide and magnesium oxide act more gently.⁶ The guideline gives magnesium oxide a conditional recommendation, noting very low certainty of evidence. Magnesium supplements deserve caution in people with kidney problems because the kidneys are responsible for clearing excess magnesium.

Lactulose, a synthetic sugar that isn’t digested, works through a similar water-drawing mechanism and has the advantage of a persistent carryover effect, meaning bowel function tends to stay improved for a while even after stopping.⁷ In the US, lactulose requires a prescription, but in many other countries it’s available over the counter. The guideline positions it as an option for people who fail or can’t tolerate OTC therapies.

Stimulant Laxatives and the Safety Myth

Bisacodyl (Dulcolax) and senna are stimulant laxatives that trigger the muscles of the colon to contract, physically pushing stool along. They work faster than fiber or osmotic laxatives, often within hours. The guideline gives bisacodyl and sodium picosulfate a strong recommendation for short-term or rescue use, and senna a conditional recommendation.¹

The widespread belief that stimulant laxatives damage the colon or cause dependence has persisted for decades, but the evidence for it is thin. A 2024 critical review found that no formal long-term studies have demonstrated structural changes in the gut’s nerve cells or muscle with bisacodyl or sodium picosulfate in humans.⁸ The old concern about “melanosis coli,” a darkening of the colon lining seen with long-term anthraquinone use (senna and cascara), is a harmless pigment change that reverses when the laxative is stopped. Similarly, osmotic laxatives like PEG and lactulose have not been associated with habit-forming properties in the research literature.⁷

That said, there is a distinction between therapeutic use and misuse. In people with eating disorders who use laxatives in high doses as a purging method, research has found reduced gut microbial diversity, which could have broader health implications.⁹ Using stimulant laxatives at recommended doses for constipation is a fundamentally different situation from chronic high-dose misuse.

Why Stool Softeners Underperform

Docusate sodium (Colace) is probably the most commonly recommended stool softener, and it’s one of the least effective options for chronic constipation. A head-to-head trial found that psyllium was clearly superior: it increased stool water content, total stool output, and overall measures of constipation relief compared with docusate.¹⁰ Another randomized trial in hospice patients found no benefit from adding docusate to senna compared with senna alone.¹¹

Despite this, docusate remains widely prescribed, partly out of habit and partly because it’s perceived as extremely gentle. If your doctor or pharmacist has recommended docusate and it’s not doing much, switching to psyllium or PEG is a reasonable conversation to have. The AGA-ACG guideline doesn’t include docusate among its recommended treatments.

Prescription Secretagogues

When OTC options have genuinely failed, prescription medications that increase fluid secretion into the intestine are the next tier. These drugs work on the cells lining the gut, prompting them to release chloride and water into the intestinal space, which softens stool and speeds transit.

Linaclotide and plecanatide are both guanylate cyclase-C agonists. They mimic a natural hormone that regulates fluid balance in the gut. The guideline gives both a strong recommendation for patients who haven’t responded to OTC agents. In two large trials, about a fifth of patients taking plecanatide achieved durable improvement in complete spontaneous bowel movements, roughly double the placebo rate. The drug also reduced straining, improved stool consistency, and decreased bloating.¹² Linaclotide has a similar profile and is also approved for constipation-predominant irritable bowel syndrome (IBS-C), making it a good choice when constipation comes with significant abdominal pain. Diarrhea is the most common side effect of both drugs, which makes sense given their mechanism.

Lubiprostone takes a different route, activating chloride channels (specifically type 2 chloride channels) in the intestinal lining. Research in healthy volunteers showed that lubiprostone accelerates both small-bowel and colonic transit.¹³ The guideline gives lubiprostone a conditional recommendation, meaning the evidence is less robust than for linaclotide or plecanatide. Nausea is its most common side effect and tends to improve if taken with food.

Prucalopride for Sluggish Colons

Prucalopride works differently from the secretagogues. It’s a serotonin receptor agonist (specifically 5-HT4) that stimulates the coordinated muscle contractions that push stool through the colon. In a randomized study comparing prucalopride to PEG, prucalopride produced roughly three times as many high-amplitude propagating contractions, the powerful squeezes that move stool long distances through the colon. It also increased the distance and velocity of those contractions.¹⁴ The AGA-ACG guideline gives prucalopride a strong recommendation for patients who haven’t responded to OTC agents.¹

This drug is particularly useful when the underlying problem is slow colonic transit rather than difficulty with the mechanics of evacuation. Headache is the most frequently reported side effect, often limited to the first few days of treatment.

Opioid-Induced Constipation Is Its Own Category

If your constipation is caused by opioid pain medications, the standard OTC-to-Rx ladder may not fully apply. Opioids slow the gut by binding to mu-opioid receptors in the intestinal wall, reducing the contractions that move stool forward and increasing fluid absorption. Regular laxatives can help, but they don’t address the root cause.

Peripherally acting mu-opioid receptor antagonists (PAMORAs) were designed specifically for this problem. These drugs block opioid receptors in the gut without crossing the blood-brain barrier, so they relieve constipation without reducing pain relief.¹⁵ A systematic review and meta-analysis confirmed that PAMORAs are the only drug class with confirmed efficacy for opioid-induced constipation in pooled data.¹⁶ The three FDA-approved PAMORAs are naloxegol, methylnaltrexone, and naldemedine. In practice, many patients with opioid-induced constipation are first tried on conventional laxatives and only move to a PAMORA if those don’t work, though guidelines support earlier use.¹⁷

When the Problem Is Pelvic Floor Dysfunction

Not all chronic constipation responds to medication because not all chronic constipation is a motility or secretion problem. Dyssynergic defecation, where the muscles of the pelvic floor and anal sphincter don’t coordinate properly during a bowel movement, is a surprisingly common cause. In this condition, the muscles that should relax during defecation instead contract, making evacuation difficult regardless of how soft the stool is.

Biofeedback therapy is the treatment of choice. In randomized controlled trials, biofeedback has outperformed both laxatives and muscle-relaxant drugs for this specific subtype.¹⁸ One trial found that 80% of biofeedback patients reported major improvement at six months compared with 22% of those treated with laxatives alone, and the benefits held at one and two years of follow-up.¹⁹ Biofeedback also reduced straining, the sensation of incomplete evacuation, and abdominal pain.

The key insight here is that someone with dyssynergic defecation can cycle through every OTC and prescription laxative without relief, not because those drugs don’t work, but because the problem was never about stool consistency or transit speed in the first place. If you feel like stool reaches the rectum but you still can’t evacuate it effectively, ask about anorectal manometry testing, which can diagnose this condition.

Constipation During Pregnancy

Constipation affects a large proportion of pregnant women, driven by hormonal changes (progesterone relaxes smooth muscle, including in the gut), iron supplementation, and the physical pressure of a growing uterus. Most laxatives have minimal systemic absorption, so they’re not expected to increase the risk of birth defects.²⁰ Bulk-forming laxatives like psyllium are generally considered the safest first option. Osmotic laxatives (PEG, lactulose) and stimulant laxatives (bisacodyl, senna) can be used occasionally or short-term, though prolonged use raises theoretical concerns about dehydration or electrolyte shifts. The newer prescription secretagogues have limited safety data in pregnancy, so they’re typically avoided.

Water and Fiber Work Together

One reason fiber supplements disappoint some people is inadequate fluid intake. A trial comparing a high-fiber diet alone versus a high-fiber diet plus increased water intake (1.5 to 2 liters per day) found that both groups improved, but the group that also boosted their water intake had significantly greater increases in stool frequency and larger reductions in laxative use.²¹ A 12-month study in elderly nursing home residents found that combining a daily fiber intake of 25 grams with controlled fluid intake nearly eliminated laxative use and improved bowel function without adverse effects on weight or nutritional status.²²

This doesn’t mean drinking extra water will cure constipation on its own. But if you’re taking fiber supplements without much fluid, you’re undermining their mechanism of action. Gel-forming fibers like psyllium need water to create the soft, bulky stool that moves easily through the colon.

The Cost Gap Between OTC and Prescription

There’s a practical reason the stepped approach matters beyond clinical evidence: cost. A cost-effectiveness analysis found that continued OTC laxative treatment for chronic idiopathic constipation cost patients roughly $3,150 per year when accounting for lost wages and out-of-pocket expenses. Prescription drugs increased insurer costs by $600 to $1,000 but actually decreased patient costs by $300 to $1,100, largely because prescription coverage shifted some of the financial burden.²³ The catch is that many insurers require patients to try and fail OTC therapies before they’ll authorize coverage for prescription alternatives, a policy called step therapy. This creates a situation where some people spend months on inadequate treatment to satisfy an insurance requirement.

Generic PEG is inexpensive, often under $15 a month. Psyllium is similarly affordable. By contrast, brand-name linaclotide or prucalopride can cost several hundred dollars per month without insurance. If your insurance requires step therapy documentation, keep a log of what you’ve tried, how long you used it, and why it was insufficient. That record can speed up prior authorization.

Vibrating Capsules and Newer Devices

One of the more unusual recent additions to the constipation toolkit is a vibrating capsule (marketed as Vibrant) that you swallow like a pill. It activates hours later in the colon and produces mechanical vibrations intended to stimulate the natural contractions that move stool. In a phase 3 trial of 312 patients, about 39% of those receiving the vibrating capsule achieved improvement in complete spontaneous bowel movements compared with 22% on placebo. Straining, stool consistency, and quality of life all improved as well, and side effects were mild and mostly gastrointestinal.²⁴

A meta-analysis of the available trials struck a more cautious note: while spontaneous bowel movements improved with the capsule, the pooled data on complete spontaneous bowel movements didn’t quite reach statistical significance.²⁵ The capsule is FDA-cleared and available by prescription. It’s most interesting for people who want to avoid daily medication entirely or who haven’t tolerated other options. It’s also drug-free, which matters for people already managing complex medication regimens.

Matching the Treatment to the Type

Chronic constipation isn’t one condition. The Rome IV criteria recognize four subtypes: functional constipation, irritable bowel syndrome with constipation (IBS-C), opioid-induced constipation, and functional defecation disorders like dyssynergic defecation.²⁶ The treatment that works well for one subtype may be irrelevant for another. Someone with IBS-C and significant abdominal pain might benefit most from linaclotide, which has pain-relieving effects in the gut beyond its laxative action. Someone with dyssynergic defecation needs biofeedback, not stronger laxatives. Someone on chronic opioids likely needs a PAMORA rather than just more PEG.

Japanese clinical guidelines lay out a useful framework: first rule out secondary causes (medications, thyroid disorders, structural problems), then determine whether the issue is a motility disorder, and then treat based on whether the dominant symptom is infrequent bowel movements or difficulty evacuating.²⁷ This diagnostic-first approach sounds obvious, but in practice, many people self-treat for years without ever identifying what kind of constipation they have. If you’ve been cycling through OTC products without lasting relief, that’s a signal to get a proper evaluation rather than to try the next product on the shelf.

1
PubMed Central. American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation
2
PubMed Central. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
3
PubMed Central. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 2: What to Look for and How to Recommend an Effective Fiber Therapy
4
PubMed. Laxative effects of wheat bran and psyllium: Resolving enduring misconceptions about fiber in treatment guidelines for chronic idiopathic constipation
5
Gut. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation
6
PubMed Central. Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review
7
F1000Research. Habit forming properties of laxatives for chronic constipation: A review
8
PubMed Central. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge
9
PubMed Central. Laxative abuse is associated with a depleted gut microbial community structure among females and males with binge-eating disorder or bulimia nervosa: The Binge Eating Genetics Initiative (BEGIN)
10
PubMed. Psyllium is superior to docusate sodium for treatment of chronic constipation
11
PubMed. Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients
12
PubMed Central. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation
13
American Journal of Physiology-Gastrointestinal and Liver Physiology. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
14
PubMed. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study
15
PubMed Central. The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety
16
PubMed. Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: Systematic review and meta-analysis
17
PubMed Central. PAMORAs in Opioid-Induced Constipation: Are We Following the Guidelines?
18
PubMed Central. Biofeedback therapy for dyssynergic defecation
19
Gastroenterology. Biofeedback Is Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor Dyssynergia
20
PubMed Central. Treating constipation during pregnancy
21
PubMed. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation
22
PubMed. Dietary fibre and fluid in the control of constipation in a nursing home population
23
American Journal of Gastroenterology. Evaluating the Impact of Cost on the Treatment Algorithm for Chronic Idiopathic Constipation: Cost-Effectiveness Analysis
24
PubMed. Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation
25
PubMed Central. Efficacy and safety of vibrating capsule in treatment of chronic idiopathic constipation: a systematic review and meta-analysis of randomized controlled trials
26
Taylor & Francis Online (Expert Review of Gastroenterology & Hepatology). An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation
27
PubMed Central. Evidence-Based Clinical Guidelines for Chronic Constipation 2023